The Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous

Intrauterine adhesion (IUA) is an endometrial fibrosis disease caused by repeated operations of the uterus and is a common cause of female infertility. In recent years, treatment using mesenchymal stem cells (MSCs) has been proposed by many researchers and is now widely used in clinics because of th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jia-ming Chen, Qiao-yi Huang, Yun-xia Zhao, Wei-hong Chen, Shu Lin, Qi-yang Shi
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	immunoregulation allogeneic MSCs autologous MSC intrauterine adhesion rejection reaction Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/21b2b2aeb8da4283a781b01b2ea4f036
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:21b2b2aeb8da4283a781b01b2ea4f036
record_format	dspace
spelling	oai:doaj.org-article:21b2b2aeb8da4283a781b01b2ea4f0362021-11-15T06:57:36ZThe Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous1664-322410.3389/fimmu.2021.785717https://doaj.org/article/21b2b2aeb8da4283a781b01b2ea4f0362021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.785717/fullhttps://doaj.org/toc/1664-3224Intrauterine adhesion (IUA) is an endometrial fibrosis disease caused by repeated operations of the uterus and is a common cause of female infertility. In recent years, treatment using mesenchymal stem cells (MSCs) has been proposed by many researchers and is now widely used in clinics because of the low immunogenicity of MSCs. It is believed that allogeneic MSCs can be used to treat IUA because MSCs express only low levels of MHC class I molecules and no MHC class II or co-stimulatory molecules. However, many scholars still believe that the use of allogeneic MSCs to treat IUA may lead to immune rejection. Compared with allogeneic MSCs, autologous MSCs are safer, more ethical, and can better adapt to the body. Here, we review recently published articles on the immunomodulation of allogeneic and autologous MSCs in IUA therapy, with the aim of proving that the use of autologous MSCs can reduce the possibility of immune rejection in the treatment of IUAs.Jia-ming ChenQiao-yi HuangYun-xia ZhaoWei-hong ChenShu LinShu LinQi-yang ShiFrontiers Media S.A.articleimmunoregulationallogeneic MSCsautologous MSCintrauterine adhesionrejection reactionImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immunoregulation allogeneic MSCs autologous MSC intrauterine adhesion rejection reaction Immunologic diseases. Allergy RC581-607
spellingShingle	immunoregulation allogeneic MSCs autologous MSC intrauterine adhesion rejection reaction Immunologic diseases. Allergy RC581-607 Jia-ming Chen Qiao-yi Huang Yun-xia Zhao Wei-hong Chen Shu Lin Shu Lin Qi-yang Shi The Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous
description	Intrauterine adhesion (IUA) is an endometrial fibrosis disease caused by repeated operations of the uterus and is a common cause of female infertility. In recent years, treatment using mesenchymal stem cells (MSCs) has been proposed by many researchers and is now widely used in clinics because of the low immunogenicity of MSCs. It is believed that allogeneic MSCs can be used to treat IUA because MSCs express only low levels of MHC class I molecules and no MHC class II or co-stimulatory molecules. However, many scholars still believe that the use of allogeneic MSCs to treat IUA may lead to immune rejection. Compared with allogeneic MSCs, autologous MSCs are safer, more ethical, and can better adapt to the body. Here, we review recently published articles on the immunomodulation of allogeneic and autologous MSCs in IUA therapy, with the aim of proving that the use of autologous MSCs can reduce the possibility of immune rejection in the treatment of IUAs.
format	article
author	Jia-ming Chen Qiao-yi Huang Yun-xia Zhao Wei-hong Chen Shu Lin Shu Lin Qi-yang Shi
author_facet	Jia-ming Chen Qiao-yi Huang Yun-xia Zhao Wei-hong Chen Shu Lin Shu Lin Qi-yang Shi
author_sort	Jia-ming Chen
title	The Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous
title_short	The Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous
title_full	The Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous
title_fullStr	The Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous
title_full_unstemmed	The Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous
title_sort	latest developments in immunomodulation of mesenchymal stem cells in the treatment of intrauterine adhesions, both allogeneic and autologous
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/21b2b2aeb8da4283a781b01b2ea4f036
work_keys_str_mv	AT jiamingchen thelatestdevelopmentsinimmunomodulationofmesenchymalstemcellsinthetreatmentofintrauterineadhesionsbothallogeneicandautologous AT qiaoyihuang thelatestdevelopmentsinimmunomodulationofmesenchymalstemcellsinthetreatmentofintrauterineadhesionsbothallogeneicandautologous AT yunxiazhao thelatestdevelopmentsinimmunomodulationofmesenchymalstemcellsinthetreatmentofintrauterineadhesionsbothallogeneicandautologous AT weihongchen thelatestdevelopmentsinimmunomodulationofmesenchymalstemcellsinthetreatmentofintrauterineadhesionsbothallogeneicandautologous AT shulin thelatestdevelopmentsinimmunomodulationofmesenchymalstemcellsinthetreatmentofintrauterineadhesionsbothallogeneicandautologous AT shulin thelatestdevelopmentsinimmunomodulationofmesenchymalstemcellsinthetreatmentofintrauterineadhesionsbothallogeneicandautologous AT qiyangshi thelatestdevelopmentsinimmunomodulationofmesenchymalstemcellsinthetreatmentofintrauterineadhesionsbothallogeneicandautologous AT jiamingchen latestdevelopmentsinimmunomodulationofmesenchymalstemcellsinthetreatmentofintrauterineadhesionsbothallogeneicandautologous AT qiaoyihuang latestdevelopmentsinimmunomodulationofmesenchymalstemcellsinthetreatmentofintrauterineadhesionsbothallogeneicandautologous AT yunxiazhao latestdevelopmentsinimmunomodulationofmesenchymalstemcellsinthetreatmentofintrauterineadhesionsbothallogeneicandautologous AT weihongchen latestdevelopmentsinimmunomodulationofmesenchymalstemcellsinthetreatmentofintrauterineadhesionsbothallogeneicandautologous AT shulin latestdevelopmentsinimmunomodulationofmesenchymalstemcellsinthetreatmentofintrauterineadhesionsbothallogeneicandautologous AT shulin latestdevelopmentsinimmunomodulationofmesenchymalstemcellsinthetreatmentofintrauterineadhesionsbothallogeneicandautologous AT qiyangshi latestdevelopmentsinimmunomodulationofmesenchymalstemcellsinthetreatmentofintrauterineadhesionsbothallogeneicandautologous
_version_	1718428480927956992

The Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous

Ejemplares similares